GlobeNewswire: Trek Therapeutics Contains the last 10 of 1 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T08:08:41ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2017/02/13/916597/0/en/Trek-Therapeutics-Announces-Oral-Presentation-of-Faldaprevir-TD-6450-and-Ribavirin-Ph2a-Trial-Results-at-the-Asian-Pacific-Association-for-the-Study-of-the-Liver-on-February-18-201.html?f=22&fvtc=4&fvtv=31500Trek Therapeutics Announces Oral Presentation of Faldaprevir, TD-6450 and Ribavirin Ph2a Trial Results at the Asian Pacific Association for the Study of the Liver on February 18, 2017 in Shanghai2017-02-13T16:48:05Z<![CDATA[Development of an affordable and accessible HCV treatment: Ph2 study of faldaprevir+TD6450+ribavirin demonstrates favorable efficacy, safety, and pharmacokinetics in patients with genotype 4 HCV infection Development of an affordable and accessible HCV treatment: Ph2 study of faldaprevir+TD6450+ribavirin demonstrates favorable efficacy, safety, and pharmacokinetics in patients with genotype 4 HCV infection]]>